Treatment of idiopathic membranous nephropathy

Nature Reviews Nephrology

Volumn 9, Issue 8, 2013, Pages 443-458

  Hofstra, Julia M ^a   Fervenza, Fernando C ^b   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORAMBUCIL; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PHOSPHOLIPASE A2 RECEPTOR; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ALTERNATIVE MEDICINE; ANTIBODY TITER; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CONSERVATIVE TREATMENT; DRUG EFFICACY; HUMAN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; PATIENT IDENTIFICATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION;

ADRENOCORTICOTROPIC HORMONE; ALGORITHMS; ALKYLATING AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTICOAGULANTS; ANTIMETABOLITES; CALCINEURIN; GLOMERULONEPHRITIS, MEMBRANOUS; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2; RENIN-ANGIOTENSIN SYSTEM;

EID: 84880919121     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.125     Document Type: Review

References (121)

1. McQuarrie, E. P., Mackinnon, B., Stewart, G. A., Geddes, C. C. Membranous nephropathy remains the commonest primary cause of nephrotic syndrome in a northern European Caucasian population. Nephrol. Dial. Transplant. 25, 1009-1010 (2010
2. Glassock, R. J. Secondary membranous glomerulonephritis. Nephrol. Dial. Transplant. 7 (Suppl. 1) 64-71 (1992
3. Jones, D. B. Nephrotic glomerulonephritis. Am. J. Pathol. 33, 313-329 (1957
4. Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G., Hunter, J. L. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. 100, 660-664 (1959
5. Kerjaschki, D., Farquhar, M. G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl Acad. Sci. USA 79, 5557-5561 (1982
6. Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053-2060 (2002
7. Beck, L. H. et al. M type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11-21 (2009
8. Hofstra, J. M., Beck, L. H. Jr, Beck, D. M., Wetzels, J. F. & Salant, D. J. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286-1291 (2011
9. Qin, W. et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137-1143 (2011
10. Stanescu, H. C. et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N. Engl. J. Med. 364, 616-626 (2011
11. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2, 186-197 (2012
12. Hofstra, J. M. & Wetzels, J. F. Management of patients with membranous nephropathy. Nephrol. Dial. Transplant. 27, 6-9 (2012
13. Ohtani, H. et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol. Dial. Transplant. 19, 574-579 (2004
14. Qu, Z. et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol. Dial. Transplant. 27, 1931-1937 (2012
15. Song, Y. S., Min, K. W., Kim, J. H., Kim, G. H. & Park, M. H. Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis. Clin. J. Am. Soc. Nephrol. 7, 1947-1955 (2012
16. Lefaucheur, C. et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 70, 1510-1517 (2006
17. Hofstra, J. M. & Wetzels, J. F. Anti-PLA2R antibodies in membranous nephropathy: Ready for routine clinical practice? Neth. J. Med. 70, 109-113 (2012
18. Hoxha, E. et al. An immunofluorescence test for phospholipase A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol. Dial. Transplant. 26, 2526-2532 (2011
19. Hladunewich, M. A., Troyanov, S., Calafati, J. & Cattran, D. C. The natural history of the non-nephrotic membranous nephropathy patient. Clin. J. Am. Soc. Nephrol. 4, 1417-1422 (2009
20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 3, 1-150 (2013
21. Polanco, N. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697-704 (2010
22. van den Brand, J. A., Hofstra, J. M. & Wetzels, J. F. Low molecular weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 2846-2853 (2011
23. Deegens, J. K. & Wetzels, J. F. Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy. Minerva Urol. Nefrol. 57, 211-236 (2005
24. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857-1863 (1997
25. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with diabetes type 2 and nephropathy. N. Engl. J. Med. 345, 681-689 (2001
26. Gansevoort, R. T., Heeg, J. E., Vriesendorp, R., de, Z. D. & de Jong, P. E. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol. Dial. Transplant. 7 (Suppl. 1), 91-96 (1992
27. Ruggenenti, P. et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am. J. Kidney. Dis. 35, 381-391 (2000
28. Ambalavanan, S., Fauvel, J. P., Sibley, R. K., Myers, B. D. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. 7, 290-298 (1996
29. Schoolwerth, A. C. et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104, 1985-1991 (2001
30. du Buf-Vereijken, P. W., Branten, A. J. & Wetzels, J. F. Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46, 1012-1029 (2005
31. Troyanov, S., Wall, C. A., Miller, J. A., Scholey, J. W. & Cattran, D. C. Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int. 66, 1199-1205 (2004
32. Rutkowski, P. et al. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 43, 260-268 (2004
33. Luno, J. et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int. Suppl. 82, S47-S52 (2002
34. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008
35. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet 377, 2181-2192 (2011
36. Sakurai, N. et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol. Dial. Transplant. 24, 2378-2383 (2009
37. Hartner, A. et al. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone acetate salt hypertension. J. Hypertens. 27, 376-385 (2009
38. Cormack-Aboud, F. C., Brinkkoetter, P. T., Pippin, J. W., Shankland, S. J. & Durvasula, R. V. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol. Dial. Transplant. 24, 404-412 (2009
39. Barbour, S. J. et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 81, 190-195 (2012
40. Lionaki, S. et al. Venous thromboembolism in patients with membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 43-51 (2012
41. Ueda, N. Effect of corticosteroids on some hemostatic parameters in children with minimal change nephrotic syndrome. Nephron 56, 374-378 (1990
42. Hofstra, J. M. et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial. Nephrol. Dial. Transplant. 25, 129-136 (2010
43. Reichert, L. J., Koene, R. A. & Wetzels, J. F. Prognostic factors in idiopathic membranous nephropathy. Am. J. Kidney Dis. 31, 1-11 (1998
44. Praga, M. & Rojas-Rivera, J. Glomerular disease: Predicting outcomes in idiopathic membranous nephropathy. Nat. Rev. Nephrol. 8, 496-498 (2012
45. Pei, Y., Cattran, D. & Greenwood, C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 42, 960-966 (1992
46. Cattran, D. C. et al. Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int. 51, 901-907 (1997
47. Branten, A. J. et al. Urinary excretion of β2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study. J. Am. Soc. Nephrol. 16, 169-174 (2005
48. van den Brand, J. A., Hofstra, J. M. & Wetzels, J. F. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 1242-1248 (2012
49. Hofstra, J. M. et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1735-1743 (2012
50. Kanigicherla, D. et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 83, 940-948 (2013
51. Beck, L. H. et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543-1550 (2011
52. [No authors listed] A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N. Engl. J. Med. 301, 1301-1306 (1979
53. Cattran, D. C. et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. 320, 210-215 (1989
54. Cameron, J. S., Healy, M. J. & Adu, D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q. J. Med. 74, 133-156 (1990
55. Ponticelli, C. et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48, 1600-1604 (1995
56. Jha, V. et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 18, 1899-1904 (2007
57. Torres, A. et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 61, 219-227 (2002
58. du Buf-Vereijken, P. W., Branten, A. J., Wetzels, J. F. & Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: Improved renal survival but high relapse rate. Nephrol. Dial. Transplant. 19, 1142-1148 (2004
59. du Buf-Vereijken, P. W. et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: High renal survival in a large patient cohort. Q. J. Med. 97, 353-360 (2004
60. Hofstra, J. M. & Wetzels, J. F. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands. Nephrol. Dial. Transplant. 23, 3534-3538 (2008
61. Cattran, D. C., Reich, H. N., Kim, S. J. & Troyanov, S. Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin. J. Am. Soc. Nephrol. 6, 591-598 (2011
62. Howman, A. et al. Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial. Lancet 381, 744-751 (2013
63. Branten, A. J., Vervoort, G. & Wetzels, J. F. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol. Dial. Transplant. 20, 707-711 (2005
64. Branten, A. J., Reichert, L. J., Koene, R. A. & Wetzels, J. F. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Q. J. Med. 91, 359-366 (1998
65. Ponticelli, C. et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 9, 444-450 (1998
66. Baltus, J. A., Boersma, J. W., Hartman, A. P. & Vandenbroucke, J. P. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up. Ann. Rheum. Dis. 42, 368-373 (1983
67. Knight, A., Askling, J., Granath, F., Sparen, P. & Ekbom, A. Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide. Ann. Rheum. Dis. 63, 1307-1311 (2004
68. Plotz, P. H. et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann. Int. Med. 91, 221-223 (1979
69. Faurschou, M. et al. Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100-105 (2008
70. Mok, C. C., Lau, C. S. & Wong, R. W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831-837 (1998
71. Pendse, S., Ginsburg, E. & Singh, A. K. Strategies for preservation of ovarian and testicular function after immunosuppression. Am. J. Kidney. Dis. 43, 772-781 (2004
72. Ioannidis, J. P., Katsifis, G. E., Tzioufas, A. G. & Moutsopoulos, H. M. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J. Rheumatol. 29, 2129-2135 (2002
73. Meistrich, M. L., Parchuri, N., Wilson, G., Kurdoglu, B. & Kangasniemi, M. Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. J. Androl. 16, 334-341 (1995
74. Wetzels, J. F. Cyclophosphamide-induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis? Neth. J. Med. 62, 347-352 (2004
75. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103-1112 (2009
76. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmatic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003
77. Western Canadian Glomerulonephritis Study Group. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Can. Med. Assoc. J. 115, 1209-1210 (1976
78. Ahuja, M., Goumenos, D., Shortland, J. R., Gerakis, A. & Brown, C. B. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am. J. Kidney Dis. 34, 521-529 (1999
79. Brown, J. H. et al. Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol. Dial. Transplant. 13, 443-448 (1998
80. Bone, J. M., Rustom, R. & Williams, P. S. 'Progressive' versus 'indolent' idiopathic membranous glomerulonephritis. Q. J. Med. 90, 699-706 (1997
81. Goumenos, D. S., Ahuja, M., Davlouros, P., El Nahas, A. M. & Brown, C. B. Prednisolone and azathioprine in membranous nephropathy: A 10-year follow-up study. Clin. Nephrol. 65, 317-323 (2006
82. Choi, M. J. et al. Mycophenolate treatment for primary glomerular disease. Kidney Int. 61, 1098-1114 (2002
83. Dussol, B. et al. Mycophenolate mofetil monotherapy in membranous nephropathy: A 1 year randomized controlled trial. Am. J. Kidney Dis. 52, 699-705 (2008
84. Miller, G., Zimmerman, R. III, Radhakrishnan, J. & Appel, G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am. J. Kidney Dis. 36, 250-256 (2000
85. Branten, A. J., du Buf-Vereijken, P. W., Vervloet, M. & Wetzels, J. F. Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am. J. Kidney Dis. 50, 248-256 (2007
86. Senthil Nayagam, L. et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol. Dial.Transplant. 23, 1926-1930 (2008
87. Chan, T. M. et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology 12, 576-581 (2007
88. Meyrier, A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol. Dial. Transplant. 7 (Suppl. 1), 80-84 (1992
89. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938 (2008
90. Cattran, D. C. et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 47, 1130-1135 (1995
91. Cattran, D. C. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int. 59, 1484-1490 (2001
92. Alexopoulos, E., Papagianni, A., Tsamelashvili, M., Leontsini, M. & Memmos, D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol. Dial. Transplant. 21, 3127-3132 (2006
93. Praga, M., Barrio, V., Juárez, G. F., Luño, J. & Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int. 71, 924-930 (2007
94. Kalliakmani, P., Koutroulia, E., Sotsiou, F., Vlachojannis, J. G. & Goumenos, D. S. Benefit and cost from the long-term use of cyclosporine A in idiopathic membranous nephropathy. Nephrology 15, 762-767 (2010
95. Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923-924 (2002
96. Fervenza, F. C. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117-125 (2008
97. Fervenza, F. C. et al. Rituximab therapy in idiopathic membranous nephropathy: A 2 year study. Clin. J. Am. Soc. Nephrol. 5, 2188-2198 (2010
98. Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C. & Remuzzi, G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2, 932-937 (2007
99. Ruggenenti, P. et al. Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738-748 (2006
100. Ruggenenti, P. et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1416-1425 (2012
101. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01180036?term=NCT01180036&rank=1 (2013
102. Segarra, A. et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin. J. Am. Soc. Nephrol. 4, 1083-1088 (2009
103. Berg, A. L., Nilsson-Ehle, P. & Arnadottir, M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 56, 1534-1543 (1999
104. Berg, A. L. & Arnadottir, M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol. Dial. Transplant. 19, 1305-1307 (2004
105. Lindskog, A. M. et al. Melanocortin 1 receptor agonists reduce proteinuria. J. Am. Soc. Nephrol. 21, 1290-1298 (2010
106. Ponticelli, C. et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney Dis. 47, 233-240 (2006
107. Bomback, A. S. et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des. Devel. Ther. 5, 147-153 (2011
108. Bomback, A. S. et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: A prospective trial. Am. J. Nephrol. 36, 58-67 (2012
109. Hladunewich, M. et al. A pilot study to determine dose, effectiveness and depletion of anti-PLA2R antibodies of adrenocorticotrophic hormone (ACTH Acthar® Gel) in subjects with nephrotic syndrome and idiopathic membranous nephropathy [abstract]. J. Am Soc. Nephrol. 23, FR-OR125 (2012
110. du Buf-Vereijken, P. W. & Wetzels, J. F. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. Nephrol. Dial. Transplant. 21, 389-396 (2006
111. Irazabal, M. V. et al. Low and high molecular weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: A prospective study. Nephrol. Dial. Transplant. 28, 137-146 (2013
112. ERA-EDTA Immunonephrology Working Group. Ongoing Projects [online], http://www.era-edta.org/immunonephrology/immunonephrology-ongoingprojects.html (2012
113. Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 2328-2337 (2012
114. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01762852?term=NCT01762852&rank=1 (2013
115. Fervenza, F. C., Glassock, R. J. & Bleyer, A. J. American Society of Nephrology Quiz and Questionnaire 2012: Glomerulonephritis. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.00440113
116. Murtas, C. et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 27, 1394-1400 (2012
117. Ballarin, J. et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: Results of a pilot study. Nephrol. Dial. Transplant. 22, 3196-3201 (2007
118. Rostoker, G. et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63, 335-341 (1993
119. Goumenos, D. S., Kalliakmani, P., Tsakas, S., Sotsiou, F. & Vlachojannis, J. G. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin. Nephrol. 61, 17-24 (2004
120. Goumenos, D. S. et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: Higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am. J. Nephrol. 27, 226-231 (2007
121. Chen, M. et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: A multicenter randomized controlled trial. Am. J. Med. Sci. 339, 233-238 (2010